Icosavax, a Phase 1 biotech developing vaccines for respiratory diseases, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.
Icosavax is developing its virus-like particle, or VLP, platform technology to develop vaccines against infectious diseases, with an initial focus on life threatening respiratory diseases. The company's pipeline includes vaccines programs targeting some of the most prevalent viral causes of pneumonia. The company's lead program is IVX-A12, a bivalent candidate targeting both respiratory syncytial virus, or RSV, and human metapneumovirus, or hMPV.
The Seattle, WA-based company was founded in 2017 plans to list on the Nasdaq under the symbol ICVX. Icosavax filed confidentially on May 14, 2021. Jefferies, Cowen, Evercore ISI, and William Blair are the joint bookrunners on the deal. No pricing terms were disclosed.
